Phase 4 Alzheimer's Disease Trial, Recruiting NCT07502560 Sponsor: GlaxoSmithKline Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 4 Alzheimer's Disease Trial, Recruiting

NCT07502560
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are permanent citizens living in Finland and who, in the investigator's opinion, are able and willing to follow the study requirements.
  • People who have given written or witnessed informed consent before any study procedures begin, including consent for the trial to access their health register data.
  • People who are 76 years of age or older at the time of signing the consent form.

Who may not be able to join:

  • People who have previously received a Herpes Zoster (shingles) vaccine.
  • People who have a confirmed dementia diagnosis, are currently being investigated for dementia, or who currently take or have previously taken medications used to treat dementia. Note: a diagnosis of mild cognitive impairment alone, without other signs of cognitive decline or dementia, does not automatically prevent participation (confirm with trial site).
  • People who have severely weakened immune systems.
  • People who are currently participating in another clinical trial involving an investigational product, or who are participating in another trial focused on preventing dementia.
  • People with a known serious allergy to any ingredient in the vaccine used in this study, or who have previously had a life-threatening reaction to this vaccine or any vaccine containing the same ingredients.
  • People who are currently living in a nursing facility.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: 877-379-3718

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Registry
ClinicalTrials.gov
Start date
31 March 2026
Est. completion
1 April 2030

Where this trial is recruiting

🇫🇮 Finland

Primary endpoints

Hazard ratio of incident dementia diagnosis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov